Therapeutic agent for disease

A disease treatment, nanocapsule technology, applied in metabolic diseases, nervous system diseases, cardiovascular system diseases, etc., can solve the problems that cannot be used as medicine

Inactive Publication Date: 2013-04-24
汤浅真
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, administration of metalloporphyrin complexes alone into living organisms has many problems in terms of safety and efficacy, and the fact is that it has not been used as a medicine so far.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent for disease
  • Therapeutic agent for disease
  • Therapeutic agent for disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0115] Example 1 (terminal cancer)

[0116] 1) animals

[0117] As animals, five 6-week-old C57BL / 6Cr Slc female mice were used for each group.

[0118] 2) Reagent

[0119] As the reagent (concentration) of the present invention, iron porphyrin complex / pH-sensitive liposome (5 mM / 36 mM) and iron porphyrin complex / DPPC-PEG liposome (5 mM / 36 mM) were used.

[0120] As the reagent (concentration) of the comparative example, mitomycin C (MMC) (0.9 mM) was used.

[0121] 3) Cancer cells

[0122] B16 melanoma cells were used.

[0123] 4) Test method

[0124] B16melanoma dispersed in PBS was injected into the footpad (sole) of a mouse (C57BL / 6, ♀, 6 weeks old) to transplant cancer. The input amount of cancer cells is 1×10 6 pcs / piece / 0.05ml. An environment where a large number of thin blood vessels such as capillaries exist is selected within the range limited to the foot pads as the place for injection.

[0125] Adherent cancer was confirmed on the 10th day after cancer cel...

Embodiment 2

[0142] Example 2 (early cancer)

[0143] 1) animals

[0144] As animals, five 6-week-old ICR female mice were used for each group.

[0145] 2) Reagent

[0146] As the reagent (concentration) of the present invention, iron porphyrin complex / PLLA was used 60wt％ - F88 micelles (5mM / 0.7wt%).

[0147] As the reagent (concentration) of the comparative example, cisplatin (CDDP) (0.9 mM) was used.

[0148] 3) Cancer cells

[0149] B16 melanoma cells were used.

[0150] 4) Test method

[0151] B16melanoma dispersed in PBS was injected into the footpad (sole) of a mouse (C57BL / 6, ♀, 6 weeks old) to transplant cancer. The input amount of cancer cells is 1 / 10 of the terminal cancer situation, that is, 1×10 5 pcs / piece / 0.05ml. An environment where a large number of thin blood vessels such as capillaries exist is selected within the range limited to the foot pads as the place for injection.

[0152] Adherent cancer was confirmed on the 10th day after cancer cell transplantation, a...

Embodiment 3

[0164] Example 3 (kidney disease)

[0165] 1) animals

[0166] As animals, 6-week-old HIGA / Nsc Slc female mice were used. As for the mice in the control group, HIGA mice were inbred and derived from ddY mice, and BALB / C mice were used according to the experimental instructions of SLC in Japan.

[0167] 2) Reagent

[0168] As the reagent (concentration) of the present invention, use

[0169] Manganese porphyrin complex / pH sensitive liposome (5mM / 36mM),

[0170] Manganese porphyrin complex / DPPC-PEG liposome (5mM / 36mM),

[0171] Manganese porphyrin complex / PLLA 80ｗt％ - F88 vesicles (100 μΜ / 0.7 wt%).

[0172] 3) Test method

[0173] Mice (HIGA / Nsc Slc, ♀, 6 weeks old) were administered 0.2ml of the drug into the tail vein every week, and urine protein and occult blood were checked once a week through a urine test, and observed for one month. In addition, for the urinalysis drug, prediction 10II (Wako Pure Chemical Industries) was used.

[0174] 4) Results

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to view more

Abstract

To provide a therapeutic agent for disease capable of delivering iron or manganese porphyrin complex possessing the ability to remove active oxygen, principally to abnormal tissue in a living body to effectively remove the active oxygen therefrom, with a high degree of pharmacological effectiveness and without side effects. [Solution] A therapeutic agent for disease containing, in nano-size nanocapsules, iron or manganese containing porphyrin complex encapsulated iron or manganese porphyrin complex nanocapsules, to treat diseases of abnormal tissue by delivering iron or manganese porphyrin complex in nanocapsules into the abnormal tissue that has a high concentration of active oxygen, without affecting normal tissue that has a low concentration of active oxygen and without side effects.

Description

technical field [0001] The present invention relates to a drug for treating diseases of abnormal tissues in a living body, and in particular to a drug for treating diseases suitable for treating abnormal tissues with high concentration of active oxygen. Background technique [0002] Various active oxygen species normally produced in the living body are said to be involved in various pathological conditions such as inflammatory diseases, neurological diseases, arteriosclerosis, cancer, and diabetes. It has free radical scavenging enzymes such as superoxide dismutase (SOD) and catalase to maintain balance. [0003] However, it is known that superoxide anion radicals (O 2 -·), said to reduce the enzymatic activity of free radical scavenging enzymes. [0004] On the other hand, for diseases such as inflammatory diseases, neurological diseases, arteriosclerosis, and diabetes, the reason is that the balance of free radical scavenging enzymes such as SOD and catalase collapses, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/555A61K9/127A61K9/51A61P3/10A61P9/10A61P25/00A61P29/00A61P35/00A61P39/06
CPCA61K9/0002A61K9/127A61K9/5107A61K31/555A61K9/51A61K9/1075A61K9/5146A61P25/00A61P29/00A61P35/00A61P39/06A61P9/10A61P3/10
Inventor 汤浅真结城理沙
Owner 汤浅真
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap